Supplementary data from: 2'-O-Galloylhyperin prevents tissue remodeling in thyroid eye disease: prospects as a thyrotropin receptor antagonist

Context: Thyroid eye disease (TED) is a challenging condition owing to relentless orbital tissue remodeling, with thyroid-stimulating hormone receptor (TSHR) in orbital fibroblasts (OFs) serving as a promising therapeutic target.
Objectives: This study seeks to discover potential TSHR inhibitors among FDA-approved drugs and evaluate their effects on TED-OFs.
Design/Participants: Adipose tissues were sourced from the patients with or without TED. Isolated OFs were cultivated in proliferation medium or stimulated for adipogenic/fibrotic differentiation in 2D/3D models, treated by 2'-O-GH (0, 5, 20, and 50μM).
Main Outcome Measures: Using structure-based virtual screening (SBVS), potential TSHR antagonists were identified. Cellular proliferation was analyzed by EdU incorporation, flow cytometry and spheroid size. Adipogenesis was determined by Oil Red O staining, Western blot and immunofluorescence. Fibrosis was assessed using woundhealing assays, Western blot and immunofluorescence. Cycli..., , , # Supplementary Material for 2'-O-Galloylhyperin prevents Tissue Remodeling in Thyroid Eye Disease: Prospects as a Thyrotropin Receptor Antagonist

[https://doi.org/10.5061/dryad.1rn8pk13p](https://doi.org/10.5061/dryad.1rn8pk13p)

## Description of the data and file structure

### Files and variables

This is supplemental materials for the published article entitled \"2'-O-Galloylhyperin prevents Tissue Remodeling in Thyroid Eye Disease: Prospects as a Thyrotropin Receptor Antagonist\".

**Supplemental Figure 1. Expression of TSHR in orbital adipose. (images on Zenodo)**

**(A)** Representative IF images of TSHR expression in orbital adipose tissues from the patients with or without TED. Similar images were obtained from three independent OF samples. Scale bar: 100μm.

**(B)** Immunoblots with TSHR in OFs from patients with or without TED (n = 3). GAPDH served as the control.

**Supplemental Figure 2. The extra effects of 2'-O-GH on inflammation and oxidative stress**

**(A)** ELISA assa...

上下文：甲状腺眼病（Thyroid eye disease, TED）因持续的眼眶组织重塑而成为棘手病症，眼眶成纤维细胞（orbital fibroblasts, OFs）中的促甲状腺激素受体（thyroid-stimulating hormone receptor, TSHR）是极具前景的治疗靶点。
研究目的：本研究旨在从美国食品药品监督管理局（Food and Drug Administration, FDA）批准的药物中筛选潜在的TSHR抑制剂，并评估其对TED来源OFs的作用效果。
研究设计/研究对象：从伴或不伴TED的患者体内获取脂肪组织。将分离得到的OFs在增殖培养基中培养，或在2D/3D模型中经成脂/成纤维化诱导刺激，并以2'-O-GH（浓度分别为0、5、20和50μM）进行处理。
主要结局指标：采用基于结构的虚拟筛选（structure-based virtual screening, SBVS）鉴定潜在的TSHR拮抗剂；通过EdU掺入实验、流式细胞术及球体尺寸分析检测细胞增殖情况；通过油红O染色、蛋白质印迹（Western blot）及免疫荧光实验评估成脂过程；通过划痕愈合实验、蛋白质印迹及免疫荧光实验评估纤维化程度。Cycli..., , , # 补充材料：《2'-O-没食子酰基高金丝桃苷可抑制甲状腺眼病中的组织重塑：作为促甲状腺激素受体拮抗剂的应用前景》

[https://doi.org/10.5061/dryad.1rn8pk13p](https://doi.org/10.5061/dryad.1rn8pk13p)

## 数据与文件结构说明
### 文件与变量
本材料为发表于题为《2'-O-没食子酰基高金丝桃苷可抑制甲状腺眼病中的组织重塑：作为促甲状腺激素受体拮抗剂的应用前景》的学术论文的补充材料。
**补充图1. 眼眶脂肪组织中TSHR的表达（Zenodo平台图片）**
**(A)** 伴或不伴TED的患者眼眶脂肪组织中TSHR表达的代表性免疫荧光图像，该结果来自3份独立的OF样本，标尺：100μm。
**(B)** 伴或不伴TED的患者OFs中TSHR的免疫印迹结果（n=3），以GAPDH作为内参对照。
**补充图2. 2'-O-GH对炎症与氧化应激的额外影响**
**(A)** ELISA检测...